Share

Vericel Corporation (VCEL.NASDAQ) AI OPINIONS & ADVISOR ANALYSIS

Read and compare the 14 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 20 September 2026Deep analysis 20 September 2026

Publisher

Russlan Ramdowar

25 min readAudit All Past Forecasts

14 AI Advisor Reports

Select an advisor report.

SynthesizerCombines all advisor views

Synthesis of 14 independent opinions

Diversity of ModelsSame approach, varied models

Diversity of FrameworksDifferent investing styles

AI Researcher

Opus 5

Universal Investor AI

The Polymath Framework

Model rating

Buy

5-Year Return Est.

+57.9%

VCEL.NASDAQ does not currently pay dividends

1. Investment Thesis — Base Case

The tension is not whether Vericel grows but what an investor should pay for growth that is decelerating by design. Management's own plan implies roughly 14% annual revenue growth to $500M by 2029 [6], down from the 20%-plus delivered since MACI's launch, while the margin ramp to high-30% adjusted EBITDA carries the real value creation. The base case assumes the franchise executes broadly on plan, the Burlington fixed-cost base is absorbed from 2028, and the share count stays roughly flat as buybacks offset compensation. Shareholders earn the compounding, not a re-rating — because the starting multiple already capitalises success.

FY2026 guidance of $330-340M scales to roughly $600M by 2031 at low-teens growth [2].
near $200M by 2030 supports about 18x enterprise value, versus 52x trailing today.
That implies roughly $63-66 per share on about 51M shares — high-single to low-double-digit annualised returns.

Historical prices and published forecast

Observed price
Published advisor forecast

Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.

View chart values

Historical prices and published forecast — published chart values
Series	Date	Value (USD)
Observed price	2021-09-15	50.2
Observed price	2021-09-19	48.4
Observed price	2021-10-13	49.6
Observed price	2021-10-17	51.8
Observed price	2021-11-02	47.9
Observed price	2021-11-22	41.5
Observed price	2021-12-08	40.6
Observed price	2021-12-16	35.6
Observed price	2021-12-20	38.3
Observed price	2021-12-28	41.5
Observed price	2022-01-13	36.0
Observed price	2022-01-21	32.8
Observed price	2022-02-22	32.7
Observed price	2022-02-26	39.6
Observed price	2022-03-02	40.7
Observed price	2022-03-14	33.8
Observed price	2022-04-03	39.0
Observed price	2022-04-11	36.3
Observed price	2022-04-19	37.4
Observed price	2022-05-09	25.4
Observed price	2022-05-17	28.7
Observed price	2022-06-02	26.8
Observed price	2022-06-06	27.1
Observed price	2022-06-18	23.5
Observed price	2022-06-30	25.2
Observed price	2022-07-20	28.4
Observed price	2022-07-24	28.5
Observed price	2022-08-01	32.0
Observed price	2022-08-17	30.5
Observed price	2022-09-06	22.6
Observed price	2022-09-18	25.8
Observed price	2022-09-26	22.9
Observed price	2022-10-04	23.7
Observed price	2022-10-16	24.6
Observed price	2022-11-01	27.4
Observed price	2022-11-09	17.65
Observed price	2022-11-25	21.3
Observed price	2022-12-11	23.6
Observed price	2022-12-27	23.5
Observed price	2022-12-31	25.3
Observed price	2023-01-08	24.0
Observed price	2023-01-20	29.0
Observed price	2023-02-05	31.1
Observed price	2023-02-09	28.3
Observed price	2023-03-09	29.9
Observed price	2023-03-17	30.7
Observed price	2023-03-29	28.2
Observed price	2023-04-10	30.5
Observed price	2023-04-14	29.8
Observed price	2023-05-04	32.7
Observed price	2023-05-12	32.8
Observed price	2023-05-24	34.4
Observed price	2023-06-01	32.5
Observed price	2023-06-21	34.7
Observed price	2023-07-07	36.8
Observed price	2023-07-15	39.0
Observed price	2023-07-19	38.6
Observed price	2023-08-04	32.0
Observed price	2023-08-12	31.8
Observed price	2023-09-01	32.8
Observed price	2023-09-05	32.6
Observed price	2023-09-13	36.7
Observed price	2023-09-29	33.5
Observed price	2023-10-07	34.2
Observed price	2023-10-27	32.8
Observed price	2023-11-04	35.8
Observed price	2023-11-20	36.7
Observed price	2023-12-06	34.7
Observed price	2023-12-10	34.2
Observed price	2023-12-26	36.3
Observed price	2024-01-03	34.4
Observed price	2024-01-23	42.3
Observed price	2024-01-31	43.0
Observed price	2024-02-16	49.2
Observed price	2024-02-20	48.3
Observed price	2024-03-11	44.6
Observed price	2024-03-15	44.2
Observed price	2024-03-31	51.6
Observed price	2024-04-08	50.2
Observed price	2024-04-20	44.6
Observed price	2024-05-06	46.9
Observed price	2024-05-22	50.3
Observed price	2024-05-26	47.6
Observed price	2024-06-15	42.6
Observed price	2024-06-19	43.9
Observed price	2024-06-27	46.9
Observed price	2024-07-25	52.4
Observed price	2024-08-02	47.1
Observed price	2024-08-06	45.6
Observed price	2024-08-26	52.5
Observed price	2024-08-30	51.0
Observed price	2024-09-11	43.7
Observed price	2024-09-23	46.4
Observed price	2024-10-01	40.0
Observed price	2024-10-17	40.7
Observed price	2024-11-06	48.0
Observed price	2024-11-14	52.7
Observed price	2024-11-22	59.1
Observed price	2024-12-12	57.7
Observed price	2024-12-20	55.5
Observed price	2025-01-01	55.2
Observed price	2025-01-13	59.6
Observed price	2025-02-06	60.1
Observed price	2025-02-10	57.7
Observed price	2025-02-18	57.3
Observed price	2025-03-06	48.8
Observed price	2025-03-10	48.9
Observed price	2025-03-30	43.8
Observed price	2025-04-03	43.5
Observed price	2025-04-07	39.9
Observed price	2025-05-01	38.5
Observed price	2025-05-17	42.7
Observed price	2025-06-02	40.5
Observed price	2025-06-10	45.7
Observed price	2025-06-14	42.0
Observed price	2025-07-04	41.4
Observed price	2025-07-20	36.7
Observed price	2025-07-28	41.5
Observed price	2025-08-13	37.9
Observed price	2025-08-21	35.4
Observed price	2025-08-29	36.4
Observed price	2025-09-14	31.9
Observed price	2025-09-26	30.3
Observed price	2025-10-08	32.9
Observed price	2025-10-12	33.3
Observed price	2025-10-20	36.2
Observed price	2025-11-05	37.5
Observed price	2025-11-13	40.1
Observed price	2025-11-29	39.4
Observed price	2025-12-19	36.0
Observed price	2025-12-31	36.4
Observed price	2026-01-08	40.7
Observed price	2026-01-20	37.7
Observed price	2026-02-05	36.5
Observed price	2026-02-13	34.5
Observed price	2026-02-21	38.2
Observed price	2026-03-09	34.1
Observed price	2026-03-25	31.4
Observed price	2026-03-29	30.8
Observed price	2026-04-18	35.2
Observed price	2026-05-04	36.5
Observed price	2026-05-12	32.9
Observed price	2026-06-01	32.8
Observed price	2026-06-05	36.3
Observed price	2026-06-09	37.0
Observed price	2026-06-29	44.9
Observed price	2026-07-11	47.2
Observed price	2026-07-23	45.0
Observed price	2026-08-04	46.3
Observed price	2026-08-16	43.8
Observed price	2026-08-24	42.3
Observed price	2026-09-09	39.0
Observed price	2026-09-22	40.2
Observed price	2026-09-23	38.8
Observed price	2026-09-25	39.7
Published advisor forecast	2026-09-18	40.0
Published advisor forecast	2026-12-18	41.6
Published advisor forecast	2027-03-18	43.7
Published advisor forecast	2027-06-18	42.4
Published advisor forecast	2027-09-18	44.9
Published advisor forecast	2027-12-18	46.7
Published advisor forecast	2028-03-18	48.1
Published advisor forecast	2028-06-18	50.1
Published advisor forecast	2028-09-18	48.1
Published advisor forecast	2028-12-18	50.5
Published advisor forecast	2029-03-18	52.5
Published advisor forecast	2029-06-18	54.1
Published advisor forecast	2029-09-18	55.1
Published advisor forecast	2029-12-18	57.3
Published advisor forecast	2030-03-18	55.6
Published advisor forecast	2030-06-18	57.8
Published advisor forecast	2030-09-18	59.6
Published advisor forecast	2030-12-18	61.4
Published advisor forecast	2031-03-18	62.6
Published advisor forecast	2031-06-18	61.3
Published advisor forecast	2031-09-18	63.2

2. Scenarios & Signals

Bull case

The bull case activates when the margin ramp arrives a year early. If Arthro conversion accelerates while opex growth flattens after the sales-force build completes in 2027, margin jumps toward 30% on $400M revenue, and the market stops debating growth and starts capitalising cash. Add an FDA ankle label or a UK launch, and the terminal addressable market widens just as rate cuts restore tolerance for long-duration multiples. Earnings and multiple then expand together — the reflexive combination that produced VCEL's prior run.

Bear case

The bear case begins with one missed December quarter. The 2026 raise is back-loaded, requiring a 15-26% Q4 acceleration; a shortfall would expose the assumption that Arthro adoption is linear. Compounding it, Burlington depreciation and expanded sales coverage are fixed, so revenue softness compresses margins faster than it compresses revenue. With the 10Y near 5%, an 84x earnings multiple offers no cushion — the stock re-rates toward 30x forward adjusted earnings, a considerably lower price, and the growth narrative resets for years.

Current crowd narrative

The consensus treats VCEL as a de-risked medtech compounder: MACI Arthro expands the surgeon base, guidance rises every quarter, and 2029 targets of $500M revenue with high-30% EBITDA margins are quoted as near-arithmetic [6]. Sell-side targets clustered at $54-$58 through July 2026 anchor to that path. The blind spot is duration: at 84x trailing earnings, the crowd debates growth while the discount rate quietly sets the price.

Alpha-gap assessment

Mildly underpriced, but the edge is narrower than the bulls claim. Evidence: a guidance raise plus a first-ever $200M buyback produced a roughly 13% de-rating from $45.96 to under $40 [11][12] — that is rate-driven repricing, not deteriorating economics. The overlooked item is cash conversion: TTM free cash flow of $49.6M already exceeds TTM EBITDA of $38.5M, so the franchise self-funds its capacity build. The offsetting blind spot most bulls ignore is that adjusted margins flatter a stock-compensation-heavy cost base, capping the GAAP earnings any future multiple can capitalise.

Convergence catalyst

The February 2027 fourth-quarter print is the hinge. It tests whether the implied $107-117M December quarter lands and whether Burlington absorption lifts gross margin toward 76%. The first observable sign of repricing is margin expanding year-over-year again after Q2 2026's decline to 19% from 21% [4].

Macro-regime alignment

The macro wind is in its face through the first forecast year. With the Fed at 3.75%-4.00% and the 10Y near 5.00%, a 52x EV/EBITDA long-duration asset carries the heaviest discount-rate burden in healthcare. Demand itself is largely rate-insensitive — elective cartilage repair is insurance-funded — so the transmission runs almost entirely through valuation, not through volumes or financing costs.

Paywalled preview begins: Macro-regime alignment

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Sentiment and regime

Greed and fear sentiment: -0.1
Expected volatility regime: high_erratic
Convergence-cycle position: stabilization

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
MACI Arthro Widens THE Surgical Funnel	The arthroscopic delivery system converts MACI from an open-arthrotomy procedure into one a sports-medicine surgeon can perform routinely, widening the target base from roughly 5,000 to 7,000 surgeons with over 900 already Arthro-trained [8]. Q2 2026 delivered record biopsies, implants and implanting surgeons, with MACI revenue up 23% to $65.5M [3]. Adoption compounds slowly because each converted surgeon becomes a recurring biopsy annuity.	Not available	+45.0%
Burlington Absorbs THE Fixed COST Burden	Autologous cell manufacturing is overwhelmingly fixed-cost: gross margin climbed from 66.8% in 2022 to 74.4% in 2025 purely on volume absorption. The new Burlington facility, entering commercial MACI manufacturing in 2026, front-loads depreciation and lease expense before the volume arrives [8]. Management reiterates high-30% adjusted EBITDA margins on $500M revenue by 2029 [6]; even partial delivery multiplies earnings against a 75% gross margin base.	Not available	+32.0%
A Regulatory MOAT Around Living Cartilag	MACI remains the only FDA-approved autologous cellularized scaffold for knee cartilage repair, and Epicel holds humanitarian device protection in massive burns; both are biologics requiring licensed manufacturing sites, not 510(k) devices. That approval architecture deters entry for years, not quarters. Pricing power follows: MACI carries premium reimbursement with no therapeutically equivalent approved substitute, which is why gross margin expands rather than erodes as volume scales.	Not available	+16.0%
NET CASH Quietly Funds THE First Buyback	Vericel ended 2025 with roughly $200M cash and investments and no debt [8], then authorized its first $200M repurchase alongside the Q2 2026 raise [2]. TTM free cash flow of $49.6M now exceeds TTM EBITDA of $38.5M, so the programme is self-funding rather than balance-sheet-eroding. Its real function is offsetting stock-compensation dilution, holding the ~50.9M share count roughly flat while earnings scale.	Not available	+12.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
THE Duration TAX ON A 52x Multiple	At 84x trailing GAAP earnings and 52x EV/EBITDA, virtually all of VCEL's value sits in terminal cash flows — maximum sensitivity to the discount rate. The Fed at 3.75%-4.00% and the US 10Y near 5.00% explain why shares fell from $45.96 in late July to under $40 in September despite a guidance raise and a buyback [11][12]. Multiple compression, not demand destruction, is the dominant price variable.	Not available	-25.0%
Adjusted Ebitda's Stock COMP Shadow	The gap between $38.5M TTM EBITDA and $49.6M TTM FCF is not operational magic; it reflects interest income on the cash pile, tax items and a large stock-based compensation add-back. Every dollar of that add-back is a real claim on shareholders, issued at elevated multiples. Management's high-30% adjusted margin target therefore overstates the GAAP earnings that ultimately support a P/E, and the buyback largely neutralises dilution rather than shrinking the float.	Not available	-10.0%
Payers WANT Outcomes NOT Human Factors	MACI Arthro's approval rested on human-factors work rather than large prospective outcome trials, and management concedes broader coverage depends on peer-reviewed and registry evidence accumulating with a lag [13]. Commercial payers and Medicare Advantage plans increasingly apply prior-authorisation gates to high-cost orthobiologics. Any coverage-policy tightening hits a single product carrying roughly 85% of revenue — concentration risk with no offsetting franchise.	Not available	-10.0%
Sales Force RAMP Outruns Revenue	Here is the anomaly: Q2 2026 adjusted EBITDA margin fell to 19% from 21% a year earlier despite 22% revenue growth [4]. Opex expansion for Arthro sales coverage, marketing and the MASCOT ankle trial is running ahead of the volume it generates, while quarterly D&A has more than doubled to $3.27M on the facility step-up. The margin ramp is back-end loaded and each delayed quarter pushes terminal value further out.	Not available	-7.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
A Strategic Buyer Takes OUT THE Platform	A scarce, FDA-approved, cash-generative cell-therapy franchise with a 75% gross margin and no debt is precisely what a large orthopaedics or sports-medicine acquirer lacks. Stryker, Smith+Nephew or J&J MedTech could fold MACI into an existing knee-and-shoulder sales channel and eliminate most of Vericel's commercial opex, making the deal accretive at a substantial premium. A bid becomes most plausible in 2028-2030, once Burlington is validated at scale and the margin ramp is evidenced. Probability stays modest: the current multiple already prices growth, deterring disciplined acquirers.	18.0%	+45.0%
Ankle Approval PLUS A UK Beachhead	The MASCOT ankle study and the Q2 2026 UK MHRA marketing-authorisation application for MACI are two independent shots at expanding a single-geography, single-joint franchise. An FDA ankle label around 2029-2030 plus a 2027-2028 UK launch would add addressable procedures without proportionate manufacturing or sales-force cost, driving incremental revenue at near-incremental-margin economics and justifying a growth-duration re-rating. It stays below 50% because trial readouts, MHRA timing and reimbursement negotiations are each independently uncertain, and management offers only 'timing and likelihood' language.	35.0%	+32.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Single Product Coverage Shock	MACI supplies roughly 85% of revenue from one product manufactured at a newly commissioned facility. A national commercial-payer coverage restriction, a CMS reassessment of cartilage-repair reimbursement, or an FDA manufacturing observation at Burlington during 2027-2029 would each strike the same cash flow. Because the valuation capitalises an uninterrupted compounding path, even a two-quarter disruption would reset both near-term earnings and the terminal multiple. It remains below 50% because the product is long-established with entrenched coverage and an unblemished regulatory record.	18.0%	-38.0%
THE BACK Loaded Fourth Quarter Misses	H1 2026 revenue of $145.9M plus Q3 guidance near $77.5M implies a Q4 print of roughly $107-117M against $92.9M a year earlier — a required 15-26% acceleration [6]. Vericel's revenue is seasonally concentrated in the December quarter, so any softness in elective knee-procedure scheduling, hospital staffing or payer authorisation converts directly into a guidance miss. At 84x trailing earnings, a growth disappointment reported in February 2027 would trigger disproportionate multiple compression. Probability stays under 50% given the record biopsy pipeline already logged.	33.0%	-26.0%

Step-by-step forecast path

Universal Investor forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_9cf29ed1-ef31-520b-bf43-150882973bb6__sb7__20260920192030834929
Step	Forecast date	Step change	Projected value (USD)	Scenario rationale
1	December 18, 2026	+4.0%	41.62	Late-October Q3 results should confirm MACI momentum near $65.5M, easing doubts about the back-loaded full-year raise. Buyback execution provides a bid, partially offsetting a 10Y yield holding near 5%.
2	March 18, 2027	+5.0%	43.70	February's fourth-quarter print is the hinge: a $107-117M December quarter and 2027 guidance above $390M validate the compounding path, driving a relief rally despite still-restrictive Fed policy.
3	June 18, 2027	-3.0%	42.39	Seasonal Q1 loss and continued Burlington depreciation compress reported margins, reminding investors the high-30% target is back-loaded. Sticky US inflation delays rate relief, pressuring long-duration healthcare multiples.
4	September 18, 2027	+6.0%	44.93	Adjusted EBITDA margin expands year-over-year for the first time since 2025 as sales-force build completes. Possible UK MHRA progress adds optionality, prompting target-price upgrades toward the low-$60s.
5	December 18, 2027	+4.0%	46.73	Third-quarter beat plus visible operating leverage sustains the re-rating. Early signs of Fed easing as energy-driven inflation fades improve the discount-rate backdrop for high-multiple smallcap medtech.
6	March 18, 2028	+3.0%	48.13	FY2027 results confirm roughly $395M revenue and mid-20% adjusted margins. Guidance for 2028 is credible but unspectacular; the stock advances with earnings rather than multiple expansion.
7	June 18, 2028	+4.0%	50.06	Burlington reaches meaningful utilisation, lifting gross margin toward 76% and converting fixed-cost absorption into visible EBITDA. Buyback continues neutralising stock-compensation dilution against a flat share count.
8	September 18, 2028	-4.0%	48.06	A quarter of slower surgeon-conversion growth revives deceleration fears heading into the 2029 target year. Elevated valuation offers no cushion, producing a sharp but fundamentally contained drawdown.
9	December 18, 2028	+5.0%	50.46	Recovery as third-quarter data show record implants and margin discipline. Speculation about the MASCOT ankle readout and possible strategic interest from large orthopaedics acquirers supports the multiple.
10	March 18, 2029	+4.0%	52.48	FY2028 results put the company within reach of the $500M/high-30% 2029 plan. Credibility on the long-range plan rather than upside surprise drives the advance.
11	June 18, 2029	+3.0%	54.05	Free cash flow scales past $110M, making the equity self-funding and expanding the repurchase pace. Valuation compresses on rising earnings even as the price grinds higher.
12	September 18, 2029	+2.0%	55.13	Growth normalises toward low-teens as the domestic knee franchise matures. Investors begin pricing the next leg — ankle and international — which remains evidence-contingent, limiting upside this quarter.
13	December 18, 2029	+4.0%	57.34	Delivery against the 2029 targets removes execution doubt. A stabilised rate environment near neutral restores tolerance for 20x-plus EBITDA multiples in profitable small-cap medtech.
14	March 18, 2030	-3.0%	55.62	Post-target-year air pocket: with the long-range plan achieved, the market demands a new growth narrative. Absent an approved ankle indication, guidance for 2030 disappoints momentum holders.
15	June 18, 2030	+4.0%	57.84	Ankle programme data or European commercial traction reopens the addressable-market debate, while high-30% margins make incremental revenue unusually accretive to per-share cash generation.
16	September 18, 2030	+3.0%	59.58	Steady compounding: revenue near $540M with roughly 37% adjusted margins. Continued repurchases hold share count flat, so earnings growth translates cleanly into per-share appreciation.
17	December 18, 2030	+3.0%	61.37	Mature-franchise pricing takes hold as investors capitalise cash flow at roughly 18-20x EBITDA. Consolidation speculation in sports-medicine biologics provides an intermittent valuation floor.
18	March 18, 2031	+2.0%	62.59	FY2030 results confirm durable cash generation but low-double-digit growth. The stock behaves like a quality compounder rather than a story stock, delivering modest, earnings-driven gains.
19	June 18, 2031	-2.0%	61.34	Payer scrutiny of high-cost orthobiologics and early competitive filings in cartilage repair create a modest multiple setback, even as underlying volumes and margins remain intact.
20	September 18, 2031	+3.0%	63.18	Horizon close with revenue near $600M and free cash flow above $150M. Valuation settles near 20x EBITDA, leaving the shares roughly 58% above the September 2026 anchor.

Advisor and configuration

Advisor: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release
Persona: Universal Investor
Archetype: The Polymath
Model: 2026-07-24 release
Provider: Anthropic
Mode: RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity
Task configuration: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__researcher__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release RESEARCHER Forecast Assembly
Input format: inmemory_base_placeholders__latest_eod_close_price_with_stats_and_fundamentals__var1
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Universal Investor advisor methodology

Configuration components

aiassmprmtcmpnt_b995bbe2-6a15-55be-a576-525904f696e8
aiassmprmtcmpnt_c55d1851-d218-5d30-b83b-54bbda31e2ee
aiassmprmtcmpnt_930157b1-05d7-5699-bf0a-738645ee42fd
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4

Research sources

[1]Vericel Reports Second Quarter 2026 Financial Results ...investors.vcel.com
[2]Press Release of Vericel Corporation ...sec.gov
[3]Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program - BioSpacebiospace.com
[4]Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program | The Manila Timesmanilatimes.net
[5]Vericel Q2 Earnings Call Highlightsfinance.yahoo.com
[6]Vericel Q2 2026 slides: 22% revenue growth, first buyback By Investing.cominvesting.com
[7]Vericel Corp (VCEL) Q2 2026 Earnings Call Transcript - Equiblesequibles.com
[8]VERICEL CORPORATION - Drug pipelines, Patents, Clinical trials - Synapsesynapse.patsnap.com
[9]Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance – Ortho Spine Newsorthospinenews.com
[10]Vericel Announces FDA Approval and Market Release of MACI Arthrosynapse.patsnap.com
[11]Vericel (NasdaqGM:VCEL) Stock Forecast & Analyst Predictions - Simply Wall Stsimplywall.st
[12]Vericel Corporation Share Price Live Today – NASDAQ:VCEL Stock Price, Chart, News, Historyupstox.com
[13]Vericel Lifts 2026 Outlook After Standout Quarter - TipRanks.comtipranks.com
[14]filing public sector pension investment board grows holdings in vericel corporation nasdaqvcel 2025 08 16marketbeat.com
[15]VCEL Stock Quote Price and Forecast | CNNcnn.com
[16]Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance | Vericel Corporationinvestors.vcel.com

Back to advisor navigation

End of the paywalled preview

The excerpt from Macro-regime alignment to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Other AI Advisor reports — limited previews

J.P. Morgan — RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity

Gemini 3.8 Flash

Limited structural preview, provided as simplified HTML. The complete report contains substantially more research: its investment thesis; bull and bear scenarios; macro-regime analysis; drivers, risks and opportunities; quarterly forecast tables and rationale; references and published configuration. Those findings and datasets are not included here. Sign in with the required subscription to open this advisor's full report.